Showing results (81-90 of 204) with videos related to
Sort By:
Pageof 21
Leukemia & Lymphoma|January 25, 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databaseKarim E Abou-Nassar, Ann Vanderplas, Jonathan W Friedberg, et al.Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.British Journal of Haematology|October 16, 2014
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantationDavid J Straus, Paul A Hamlin, Matthew J Matasar, et al.British Journal of Haematology|July 24, 2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphomaJohn Gerecitano, Carol Portlock, Craig Moskowitz, et al.Blood Advances|March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patientsJoachim Yahalom, Amy J Xu, Ariela Noy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphomaOwen A O'Connor, John Wright, Craig Moskowitz, et al.Blood|November 15, 2003
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomasJane Houldsworth, Adam B Olshen, Giorgio Cattoretti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesOwen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.British Journal of Haematology|October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor, Paul A Hamlin, Carol Portlock, et al.Pageof 21